PolyPid Ltd.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- PolyPid Ltd. (Nasdaq: PYPD) is a clinical-stage biopharmaceutical company that develops, manufactures and commercializes novel, locally administered prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology platform, which enables controlled drug delivery over days to months directly to surgical sites for conditions including infection, pain, inflammation and cancer; lead product candidate D-PLEX100 delivers doxycycline antibiotic to prevent surgical site infections (SSIs) in abdominal colorectal surgery, while OncoPLEX targets intra-tumoral cancer treatment in preclinical development, with the PLEX platform accommodating small molecules, proteins, peptides and nucleic acids. Founded in 2008 and headquartered in Petach Tikva, Israel, the company operates globally with a focus on surgical outcomes and healthcare-acquired infections like SSIs, targeting surgeons, hospitals and patients in the United States and Europe through planned NDA and MAA submissions. In 2025, PolyPid received a positive DSMB recommendation to conclude its pivotal SHIELD II Phase 3 confirmatory trial for D-PLEX100 at 800 patients with top-line results anticipated in Q2, raised $14.5 million in a PIPE financing led by institutional investors extending cash runway to Q3 2025, initiated a research and development collaboration with ImmunoGenesis Inc. leveraging PLEX and STING agonist technology for solid tumor treatments, and advanced commercialization preparations alongside U.S. partnership discussions.
Company News
PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data
PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data
European Medicines Agency Validates PolyPid's Marketing Authorization Application for D-PLEX₁₀₀
PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities
PolyPid Announces Participation in Upcoming Fall Investor Conferences
PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript
PolyPid Q2 Earnings Call Highlights
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
PolyPid, Azurity sign surgical site infection drug deal
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
PolyPid Q1 Earnings Call Highlights
PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026